Upload
unity-ballard
View
62
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Evaluation of new rapid fourth generation point of care test device for the early diagnosis of HIV infection. Alere TM HIV Combo. Yuko Tamanoue, Product Development Department. Alere™ HIV Combo- Rationale. - PowerPoint PPT Presentation
Citation preview
www.aids2014.org
Evaluation of new rapid fourth generation point of care test device for the early diagnosis of HIV infection
AlereTM HIV Combo
Yuko Tamanoue, Product Development Department
www.aids2014.org
Alere™ HIV Combo- Rationale
• Acute infection accounts for 5-20% of all cases of HIV infection among person seeking testing.
• The seroconversion window period is associated with peak levels of viremia and high risk of transmission
• Earlier identification would:– Increase case finding– Facilitate earlier referral to care– Earlier Treatment– Partner Notification
www.aids2014.org
Seroconversion Panels19 panels 3rd generation
rapid test (Ab)
FDA- approved HIV 4th generation
(Ag/Ab)
HIV EIA Ag (Ag)
Alere HIV Combo (Ag/Ab)
Earlier 16 0 2
Same 3 9 10
Later 0 2 0
Total panels 19 11 12
PCR
↓ ↓ ↓
Day -5.3 -0.6 0↑ ↑ Ag EIA
Alere HIVCombo
3rdgeneration
FDA approved4th generation
+6.7+0.6
www.aids2014.org
Acute HIV infection
RNAFDA- approved
HIV 4th generation (Ag/Ab)
Alere HIV ComboNo. of positive samples
Judge S/CO No. of positive Judge Ab Ag %
P N <1 3 N 17 17 NA
P 1~<5 18 P 1 5 33.3%
P 5~<10 10 P 0 8 80.0%
P 10~<20 8 P 0 8 100.0%
P 20~<50 15 P 2* 15 100.0%
P 50~621 15 P 3* 15 100.0%
69 Positive 66 Positive 52 78.8%* Both Ag/Ab positive
www.aids2014.org
Analytical sensitivity of HIV-1 p24 and subtype detection
• Analytical sensitivity of HIV-1 p24: 2 IU/ml• HIV-1 antibody subtype panels:
100% (40/40),
A, B, C, D, CRF01-AE, CRF02-AG, F, G, H, J, K, O
• HIV-1 virus subtype panel for antigen:
100% (31/31)
A, B, C, D, CRF01-AE, CRF02-AG, F, G, H, O
www.aids2014.org
Specificity
SampleSample
No.
Alere HIV ComboNo. of positive
Ab Ag
HIV negative specimens (US) 1099 0 1
HIV negative specimens (Africa) 150 0 0
Disease state other than HIV and potentially interfering substances 346 0 0
Total 1595 0 1
Specificity 99.9%
www.aids2014.org
Conclusions
• Alere™ HIV Combo shows comparable performance to FDA-approved 4th generation laboratory assay
• Alere™ HIV Combo shows marked improvement in case finding over 3rd generation poc test
• Alere™ HIV Combo could be a useful diagnostic tool in HIV screening programmes worldwide